

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

Full title: **Palliative care in the treatment of women with breast cancer: a scoping review protocol**

Short Title: **Palliative care in the treatment of women with breast cancer**

Authors:

Romel Jonathan Velasco-Yanez¹, RN, Master student. E-mail: romebarce_95@hotmail.com

Ana Fátima Carvalho Fernandes¹, RN, Ph.D. E-mail: afcana@ufc.br

Samuel Miranda Mattos², BPEd, Ph.D student. E-mail: profsamuelmattos@gmail.com

Thereza Maria Magalhães Moreira², RN, Ph.D. E-mail: thereza.moreira@uece.br

Régia Christina Moura Barbosa Castro¹, RN, Ph.D. E-mail: afcana@ufc.br

Luís Carlos Lopes-Júnior^{3*}, RN, Ph.D. E-mail: regiabarbosa@hotmail.com

Affiliations:

¹ Department of Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil

² Graduate Program in Public Health, Ceará State University, Fortaleza, Ceará, Brazil

³ Department of Nursing, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil

Corresponding author: Dr. Luís Carlos Lopes-Júnior (RN., OCN., MSc., Ph.D.). Adjunct Professor of the Nursing Department at Health Sciences Center, and Graduate Program in Public Health at the Federal University of Espírito Santo (UFES), Av. Marechal Campos, 1468 – Maruípe, Zip Code: 29.043-900, Vitória, ES, Brazil. E-mail: [lopesjr.lc@gmail.com] Phone: +55(27)99249-7217. ORCID: <https://orcid.org/0000-0002-2424-6510>

Author Contributions

Conceptualization: RJV-Y and AFCF

Methodology: LCLJ

Resources: AFCF

Acquisition/interpretation of data for the work: RJV-Y, AFCF, SMM, TMMM, RCMBC and LCLJ

Supervision: AFCF and LCLJ

Writing – original draft: RJV-Y, AFCF and LCLJ

Writing – review & editing, and approving the final version: RJV-Y, AFCF, SMM, TMMM, RCMBC and LCLJ

Guarantors: AFCF and LCLJ

Competing interests: The authors have declared that no competing interests exist.

Acknowledgements: None to declare.

Patient consent for publication: Not required

Word Count: 2228 words.

Patient consent: Not required.

Provenance and peer review: Not commissioned; externally peer reviewed.

ABSTRACT49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

Introduction: Palliative care is an approach that improves patients' quality of life and their families when they face problems inherent to a life-threatening illness. In the current scenario where breast cancer ranks first among the most common types of cancer in women, research has revealed little control by these patients over the symptoms of the disease and its treatment, resulting in poor quality of life, which should be the focus of attention of palliative care. Thus, the purpose of this study is to map and synthesize the available evidence on palliative care in treating breast cancer women.

Methods: This scoping review protocol was elaborated following the methodological recommendations proposed by the Joanna Briggs Institute (JBI) and the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist. All study designs, experimental studies, observational studies, qualitative studies, mixed studies, and reviews reporting the palliative care for breast cancer women, will be considered. The following electronic databases will be searched: MEDLINE (via PubMed), Embase, Cochrane Library, Web of Science, Scopus, JBI Evidence Synthesis, Epistemonikos, CINAHL (via EBSCO), LILACS, and the electronic repository SciELO. In addition, The British Library, Google Scholar, Preprints for Health Sciences [medRxiv], Open Grey, Who Library Database, ProQuest Global Dissertations and Theses, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform will be searched. No language or date restriction will be applied in the search strategy. Two investigators will independently select studies and perform data extraction and critical appraisal using the using JBI design-specific tolos. A narrative synthesis of the evidence will be carried out and will be grouped and presented in tables and graphic models. Also, a similarity analysis will be performed using IRaMuTeQ software version 0.7 alpha 2, leading to textual categories and themes.

Expected Results: The findings of this review will help to identify the gaps for the design of future primary research on women with breast cancer in palliative care. Ultimately, will position care services, managers, and health professionals in the knowledge of the phenomenon, so that they can implement the best evidence-based palliative care practices and improve the quality of care provided to breast cancer patients.

Open Science Framework Registration: osf.io/5bwq7

Keywords: Women; Breast cancer; Palliative care; Scoping review.

95 Introduction

96

97 Talking about palliative care (PC) today is an interesting challenge due to the complex
98 heterogeneity of conceptions that emerge from this term. However, PC is not a new concept.
99 Saunders [1], the forerunner of the "modern philosophy of hospice," already emphasized in
100 1978 the importance of PC in the care of patients with serious illnesses, a premise that
101 today, with the increase in life expectancy and scientific progress of medical sciences has
102 become more relevant. The growing incidence-prevalence of chronic-degenerative diseases
103 has prolonged the "death process", making it essential to integrate PC into care process
104 towards the end of life.

105 It stands out that only 14% of people who need palliative care receive it worldwide.
106 It is estimated that, annually, 40 million people need PC; 78% of them live in low- and middle-
107 income countries that lack training and awareness of PC among health professionals, a
108 major obstacle in addition to the lack of public and government policies aimed at the
109 implementation of PC at the different levels of health care [2].

110 Palliative care aims to improve the quality of life (QoL) of patients and their families
111 when facing life-threatening situations, and it is essential to improve the well-being, comfort,
112 and dignity of these individuals [3]. In this sense, PC becomes necessary in the therapeutic
113 approach of people with chronic diseases and, despite the negative or passive connotation
114 of the term, palliative treatment must be eminently active, for example, in patients with
115 advanced cancer, who need surgical and radiotherapy treatments to achieve cancer
116 symptom clusters control [4–6].

117 Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding
118 nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding
119 nonmelanoma skin cancer) occurred in 2020 [7]. Female breast cancer has surpassed lung
120 cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases
121 (11.7%) [7]. Thus, breast cancer may be of interest for the development of research in the
122 areas of diagnosis, treatment, disease control, and palliative care.

123 The diagnosis of breast cancer harms the life of women, who experience feelings of
124 fear and suffering throughout the entire process, from diagnosis to therapeutic and survival
125 stages [8,9]. In this context, PC aims to improve chronic disease patients' and families' QoL,
126 helping alleviate symptoms and maintain disease control, thus achieving a balance between
127 progression and the discomfort caused by the medical treatment [10].

128 Studies conducted by Kokkone et al. [11] and the updated Clinical Practice Guideline
129 of the American Society of Clinical Oncology [12] recommend that inpatient and outpatient

130 patients with advanced cancer should receive specific palliative care services, early in the
131 course of the disease, at the same time as active treatment. However, this recommendation
132 is not always met, especially in developing countries with an unmet need for PC [13,14].

133 Despite the strong degree of recommendation to include PC from diagnosis, recent
134 studies evaluating the QoL in women with breast cancer [8,15–20] have shown a high
135 prevalence of symptoms such as pain, anxiety, fear, cancer-related fatigue, insomnia,
136 dyspnea, and sexual dysfunction, among others. This leads us to think about the current
137 role that PC plays in the treatment of breast cancer, how they are being addressed in this
138 population and their impact on these women's lives.

139 In addition, it is important to know the role that PC plays in the healthcare of
140 vulnerable populations, in line with the third Objective of Sustainable Development [21]: "To
141 enable everyone to live in good health and promote the well-being of all at all ages". Hence,
142 the purpose of this scoping review is to map and synthesize the available evidence on
143 palliative care in treating breast cancer women. The following specific will guide the review:

- 144 • What is the scope of the evidence on guidelines or protocols that direct the
145 delivery of palliative care in women with breast cancer?
- 146 • What is the extent of the literature on the QoL benefits for women with breast
147 cancer receiving palliative care?

148

149

150 **Materials and methods**

151

152 **Design**

153

154 This is a scoping review following the methodological recommendations proposed by
155 the Jonna Briggs Institute (JBI) [22] based on the initial definition of the method proposed
156 by Arskey & O'Malley [23] (Figure 1) as well as the PRISMA Extension for Scoping Reviews
157 (PRISMA-ScR) checklist [24]. The protocol was registered in Open Science Framework
158 (Registration number: osf.io/5bwq7).

159

160

161

162

163

164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200





Figure 1. Steps of the scoping review methodology

Literature review question

The Population, Concept, Context (PCC) framework proposed by the Jonna Briggs Institute (JBI) was used for the construction of the research question [22] as follows: P – young, adult, and older women, C – palliative care, and C – breast cancer, resulting in the following research question: What is the available evidence on palliative care in the treatment of women with breast cancer?

Inclusion criteria

All studies addressing the variables of the PCC acronym will be included, without restricting the methodological design (e.g., experimental, quasi-experimental, prospective and retrospective cohort, case-control, cross-sectional, case series, individual case reports, descriptive, qualitative, mixed studies, reviews), and no language or publication date restriction. (Figure 2).



201
202 **Figure 2. Inclusion criteria aligned with the acronym PCC**
203

204 **Figure 2.** Inclusion criteria according to acronym PCC.

205
206 **Participants:** All studies addressing women, from a young age, will be included,
207 according to the age classification proposed by the WHO: "young age: 25 to 44 years, middle
208 age: 44 to 60 years, elderly age: 60 to 75 years, senile age: 75-90, and long-livers: after 90"
209 [25]. This distinction was made because the highest incidence of breast cancer occurs in
210 women \geq 40 years (26).

211 **Concept:** Studies in line with the referential framework of palliative care described
212 by the WHO will be included [2], defined as "an approach that improves the quality of life of
213 patients and their families facing the problems associated with life-threatening illness
214 through the prevention and relief of suffering by means of early identification, assessment,
215 and treatment of pain and other problems, physical, psychosocial, and spiritual".

216 **Context:** All studies addressing breast cancer will be included, without restricting the
217 type of cancer or stage, according to the definition proposed by the WHO [27]. "Breast
218 cancer arises in the lining cells (epithelium) of the ducts (85%) or lobules (15%) in the
219 glandular tissue of the breast. Initially, the cancerous growth is confined to the duct or lobule

220 ("in situ"), where it generally causes no symptoms and has minimal potential for spread
221 (metastasis). Over time, these in situ (stage 0) cancers may progress and invade the
222 surrounding breast tissue (invasive breast cancer) then spread to the nearby lymph nodes
223 (regional metastasis) or to other organs in the body (distant metastasis)".

224

225 **Exclusion criteria**

226 Studies whose participants have breast cancer diagnosed with other pathologies will
227 be excluded. In addition, studies with male patients with breast cancer will also be excluded.

228

229 **Search strategy**

230 The search strategy will be carried out systematically in eight electronic databases:
231 MEDLINE (Via PubMed), Embase (Excerpta Medica Database), LILACS (Latin American
232 and Caribbean Health Sciences Literature), Cochrane Library, Web of Science, Scopus, JBI
233 Evidence Synthesis, Epistemonikos, CINAHL (Cumulative Index to Nursing and Allied
234 Health Literature via EBSCO), as well as the electronic repository SciELO (Scientific
235 Electronic Library Online). It is emphasized that there will be no date or language restrictions
236 in the search strategy. In addition to the electronic databases mentioned above, other
237 sources will be also searched including: The British Library, Google Scholar, Preprints for
238 Health Sciences [medRxiv], Open Grey, Who Library Database, ProQuest Global
239 Dissertations, and Theses, ClinicalTrials.gov, and the WHO International Clinical Trials
240 Registry Platform.

241 Due to the flexibility of including gray literature in scoping reviews [22] and the
242 importance of knowing the role of PC in breast cancer, gray literature will also be included
243 [28], such as clinical practice guidelines, protocols, and information contained in the
244 websites of recognized scientific societies that deal with breast cancer and PC.

245 In addition, the final reference list from the included primary studies will be manually
246 scanned to find relevant studies. Two researchers will search independently, according to
247 the JBI guidelines [22]. Initially, we will identify the existence of an index of specific subject
248 in each database (with MeSH terms, Emtree, DeCS, and CINAHL headings) and their
249 synonyms (keywords). The search terms will then be combined using the Boolean operators
250 "AND" and "OR" [29,30].

251 The pilot search strategy elaborated with the help and validation of a librarian
252 combining controlled MeSH descriptors and keywords used in MEDLINE/PubMed is as
253 follows:

254

255 P- POPULATION:

256 #1 ((Women) [MeSH Terms] OR Woman [All Fields] OR Female [MeSH Terms] OR
257 Females [All Fields]))

258 C- CONCEPT: palliative care

259 #2 ((Palliative care [MeSH Terms] OR Care, palliative [All Fields] OR Palliative
260 treatment [All Fields] OR Palliative treatments [All Fields] OR Treatment palliative [All Fields]
261 OR Treatments palliative [All Fields] OR Therapy palliative [All Fields] OR Palliative therapy
262 [All Fields] OR Palliative Medicine [MeSH Terms] OR Palliative care medicine [All Fields]
263 OR Palliative supportive care [All Fields] OR Supportive care, palliative [All Fields] OR
264 Supportive care [All Fields] OR Palliative surgery [All Fields] OR Surgery, palliative [All
265 Fields] OR Cancer palliative therapy [All Fields]))

266 #1 AND #2

267 C- CONCEPT:

268 #3 ((Breast neoplasms [MeSH Terms] OR Breast neoplasm [All Field] OR Breast
269 tumors [All Fields] OR Breast tumor [All Fields] OR Breast cáncer [All Fields] OR Mammary
270 cancer [MeSH Terms] OR Cancer of breast [All Fields] OR Cancer of the breast [All Fields]
271 OR Mammary carcinoma, human [All Fields]] OR Human mammary carcinomas [All Fields]
272 OR Human mammary carcinoma [All Fields] OR Human mammary neoplasm [All Fields]
273 OR Human mammary neoplasms [MeSH Terms] OR Breast carcinoma [All Fields] OR
274 Breast carcinomas [All Fields] OR Breast malignant neoplasm [All Fields] OR Malignant
275 tumor of breast [All Fields] OR Breast malignant tumors [All Fields] OR Advanced breast
276 cancer [All Fields]))

277 #3 #1 AND #2

278

279 **Selection of the sources of evidence**

280 Rayyan Systems Inc. (RAYYAN) software will use in order to manage the sources of
281 evidence [31]. Initially, all the articles from the general search will be deposited in the
282 RAYYAN software. Then, the duplicates will be removed, and a representative sample of
283 the articles will be taken to evaluate the level of concordance and report the degree of
284 agreement between the two reviewers. Cohen's kappa coefficient will be used to estimate
285 the index of agreement between the 2 evaluators in each review phase [32].

286 After this phase, the articles will be assessed by titles and abstracts by two
287 independent researchers to identify potentially eligible articles, and another reviewer will
288 resolve any uncertainty regarding the inclusion of a study. Two reviewers will independently

289 examine the full manuscripts that passed the first selection, and a third reviewer will resolve
290 any decision conflict to obtain a definitive list of studies.

291

292 **Data charting**

293 The data will be extracted through a form designed by a research team member
294 adapted to the data extraction template proposed by the JBI and considering previously
295 published extraction forms [29,33-36]. The information to be extracted includes a) study
296 identification and objectives; b) study population and baseline characteristics; c) study
297 design; d) sample size; e) results; f) main findings; g) clinical and epidemiological
298 significance; h) conclusions, i) implications, and j) limitations. Two independent reviewers
299 will extract the data from the included studies.

300

301 **Methodological appraisal of included studies**

302 The hierarchy of evidence [37] will classify the selected studies. This classification is
303 divided into seven hierarchical levels, as described in Table 1.

304 **Table 1.** Hierarchy of evidence.

Evidence level	Study design
I	Evidence from systematic reviews or meta-analyses of randomized controlled clinical trials (RCTs)
II	Evidence from a well-designed RCT
III	Evidence from well-designed controlled clinical trials without randomization
IV	Evidence from well-designed case-control, cohort, or cross-sectional studies
V	Evidence from systematic reviews of qualitative and descriptive studies
VI	Evidence from a single descriptive or qualitative study
VII	Evidence from the opinion of authorities or reports of expert committees

305

306 Two independent reviewers will assess the methodological quality of the studies
307 using JBI design-specific tools [38]. Disagreements will be addressed by the third reviewer.

308

309

310

311

312


313

314

Data analysis and Synthesis of results

315

A flowchart diagram (Figure 3) will describe the entire study selection process [39].



316

Figure 3. PRISMA flowchart.

317

318

319

320

321

322

323

A narrative synthesis of the evidence will be carried out, and the primary quantitative data of the included studies will be tabulated. The results will be grouped and presented in tables, and graphic models. Similarity analysis obtained using the IRaMuTeQ software version 0.7 alpha 2 (Interface de R pour les Analyses Multidimensionnelles de Textes et de Questionnaires) will be carried out through textual categories, as appropriate, to define the final themes.

324

Discussion and dissemination

325

326

327

328

329

330

331

Palliative care is essential in treating women with breast cancer, not only because it comprehensively addresses their symptoms but also because it improves their quality of life, and its delivery must be initiated from the diagnosis of the disease. The findings of this review will help to identify the gaps for the design of future research on PC in breast cancer. Ultimately, will position care services, managers, and health professionals in the knowledge of the phenomenon, so that they can implement the best evidence-based PC, consequently improving the quality of care provided to breast cancer patients.

332

333

334

335

336

As strong points, this scoping review follows all the methodological recommendations proposed by the JBI. An extensive literature search will be conducted in 9 databases 1 electronic repository. A librarian will guide search strategies, and the final version of this protocol was reviewed and approved by a group of 3 specialists: a breast cancer specialist, a PC specialist, and a scoping review specialist.

337 **References**

- 338 1. Saunders C. The philosophy of terminal care. The management of terminal malignant
339 disease. 1984;2:232–41.
- 340 2. Organización Mundial de la Salud. Cuidados paliativos. Cuidados Paliativos. 2020.
341 Disponível em: <https://www.who.int/es/news-room/fact-sheets/detail/palliative-care>
- 342 3. Organización Mundial de la Salud, Organización Panamericana de la Salud.
343 Cuidados Paliativos [Internet]. Pan American Health Organization / World Health
344 Organization. 2016. Disponível em:
345 https://www3.paho.org/hq/index.php?option=com_content&view=article&id=12587:palliative-care&Itemid=42139&lang=es
- 346
- 347 4. Instituto Nacional de Câncer. Cuidados paliativos. INCA - Instituto Nacional de
348 Câncer. 2018. Disponível em: <https://www.inca.gov.br/controle-do-cancer-do-colo-do-utero/acoes-de-controle/cuidados-paliativos>
- 349
- 350 5. Lopes-Júnior LC, Rosa GS, Pessanha RM, Schuab SIPC, Nunes KZ, Amorim MHC.
351 Efficacy of the complementary therapies in the management of cancer pain in palliative care:
352 A systematic review. *Rev Lat Am Enfermagem*. 2020 Sep 30;28:e3377. doi: 10.1590/1518-
353 8345.4213.3377.
- 354 6. Lopes-Júnior LC, Tuma MC, Amorim MHC. Psychoneuroimmunology and oncology
355 nursing: a theoretical study. *Rev Esc Enferm USP*. 2021 Sep 10;55:e20210159.
- 356 7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
357 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
358 for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209-249. doi:
359 10.3322/caac.21660.
- 360 8. Lopes JV, Bergerot CD, Barbosa LR, Calux NMCT, Elias S, Ashing KT, Domenico
361 EBL. Impact of breast cancer and quality of life of women survivors. *Rev Bras Enferm*. 2018
362 Nov-Dec;71(6):2916-2921. doi: 10.1590/0034-7167-2018-0081.
- 363 9. Abrahão CA, Bomfim E, Lopes-Júnior LC, Pereira-da-Silva G. Complementary
364 Therapies as a Strategy to Reduce Stress and Stimulate Immunity of Women With Breast
365 Cancer. *J Evid Based Integr Med*. 2019 Jan-Dec;24:2515690X19834169. doi:
366 10.1177/2515690X19834169.
- 367 10. Drageset S, Austrheim G, Ellingsen S. Quality of life of women living with metastatic
368 breast cancer and receiving palliative care: A systematic review. *Health Care Women Int*.
369 2021 Sep;42(7-9):1044-1065. doi: 10.1080/07399332.2021.1876063.
- 370 11. Kokkonen K, Tasmuth T, Lehto JT, Kautiainen H, Elme A, Jääskeläinen AS, Saarto
371 T. Cancer Patients' Symptom Burden and Health-related Quality of Life (HRQoL) at Tertiary
372 Cancer Center from 2006 to 2013: A Cross-sectional Study. *Anticancer Res*. 2019
373 Jan;39(1):271-277. doi: 10.21873/anticancer.13107.
- 374 12. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of
375 Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical
376 Practice Guideline Update. *JCO* 2017;35(1):96–112. Disponível em:
377 <https://ascopubs.org/doi/10.1200/JCO.2016.70.1474>
- 378 13. Reid EA, Gudina EK, Ayers N, Tigineh W, Azmera YM. Caring for Life-Limiting Illness
379 in Ethiopia: A Mixed-Methods Assessment of Outpatient Palliative Care Needs. *J Palliat*
380 *Med*. 2018 May;21(5):622-630. doi: 10.1089/jpm.2017.0419.
- 381 14. Kaba M, de Fouw M, Deribe KS, Abathun E, Peters AAW, Beltman JJ. Palliative care
382 needs and preferences of female patients and their caregivers in Ethiopia: A rapid program

- 383 evaluation in Addis Ababa and Sidama zone. *PLoS One*. 2021 Apr 22;16(4):e0248738. doi:
384 10.1371/journal.pone.0248738.
- 385 15. Haddou Rahou B, El Rhazi K, Ouasmani F, Nejjari C, Bekkali R, Montazeri A, Mesfioui
386 A. Quality of life in Arab women with breast cancer: a review of the literature. *Health Qual
387 Life Outcomes*. 2016 Apr 27;14:64. doi: 10.1186/s12955-016-0468-9.
- 388 16. Villar RR, Fernández SP, Garea CC, Pillado MTS, Barreiro VB, Martín CG. Quality of
389 life and anxiety in women with breast cancer before and after treatment. *Rev Lat Am
390 Enfermagem*. 2017 Dec 21;25:e2958. doi: 10.1590/1518-8345.2258.2958.
- 391 17. Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas
392 D, Nagele E, Bjelic-Radisic V, Cardoso F, Sprangers MAG, Velikova G, Bottomley A;
393 European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
394 Group; Breast Cancer Group; EORTC Headquarters. Health-related quality of life in locally
395 advanced and metastatic breast cancer: methodological and clinical issues in randomised
396 controlled trials. *Lancet Oncol*. 2016 Jul;17(7):e294-e304. doi: 10.1016/S1470-
397 2045(16)30099-7.
- 398 18. Mokhtari-Hessari P, Montazeri A. Health-related quality of life in breast cancer
399 patients: review of reviews from 2008 to 2018. *Health Qual Life Outcomes*. 2020 Oct
400 12;18(1):338. doi: 10.1186/s12955-020-01591-x.
- 401 19. Salibasic M, Delibegovic S. The Quality of Life and Degree of Depression of Patients
402 Suffering from Breast Cancer. *Med Arch*. 2018 Jun;72(3):202-205. doi:
403 10.5455/medarh.2018.72.202-205.
- 404 20. Guerra RL, Dos Reis NB, Corrêa FM, Fernandes MM, Ribeiro Alves Fernandes R,
405 Cancela MC, Araújo RM, Crocamo S, Santos M, De Almeida LM. Breast Cancer Quality of
406 Life and Health-state Utility at a Brazilian Reference Public Cancer Center. *Expert Rev
407 Pharmacoecon Outcomes Res*. 2020 Apr;20(2):185-191. doi:
408 10.1080/14737167.2019.1621752.
- 409 21. Organización Mundial de la Salud. Objetivo 3: Garantizar una vida sana y promover
410 el bienestar para todos en todas las edades. *Objetivos del Desarrollo Sostenible*. 2020.
411 Disponible em: <https://www.un.org/sustainabledevelopment/es/health/>
- 412 22. Aromataris E, Munn Z, Org. JBI Manual for Evidence Synthesis [Internet]. JBI; 2020.
413 Disponible em: <https://wiki.jbi.global/display/MANUAL>
- 414 23. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.
415 *Implement Sci*. 2010 Sep 20;5:69. doi: 10.1186/1748-5908-5-69. PMID: 20854677; PMCID:
416 PMC2954944.
- 417 24. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters
418 MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L,
419 Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV,
420 Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for
421 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018 Oct
422 2;169(7):467-473. doi: 10.7326/M18-0850.
- 423 25. Zhaoyang R, Sliwinski MJ, Martire LM, Smyth JM. Age differences in adults' daily
424 social interactions: An ecological momentary assessment study. *Psychol Aging*. 2018
425 Jun;33(4):607-618. doi: 10.1037/pag0000242. Epub 2018 Apr 30. PMID: 29708385;
426 PMCID: PMC6113687.
- 427 26. Coughlin SS. Epidemiology of Breast Cancer in Women. In: Ahmad A, organizador.
428 *Breast Cancer Metastasis and Drug Resistance: Challenges and Progress*. Cham: Springer

- 429 International Publishing; 2019:9–29. Disponível em: [https://doi.org/10.1007/978-3-030-](https://doi.org/10.1007/978-3-030-20301-6_2)
430 [20301-6_2](https://doi.org/10.1007/978-3-030-20301-6_2)
- 431 27. Organización Mundial de la Salud. Câncer de mama. Câncer de Mama. 2021.
432 Disponível em: <https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer>
- 433 28. Botelho RG, Oliveira C da C de. Literaturas branca e cinzenta: uma revisão
434 conceitual. *Ciência da Informação*. 2015;44(3). Disponível em:
435 <http://revista.ibict.br/ciinf/article/view/1804>
- 436 29. Lopes-Júnior LC, Siqueira PC, Maciel ELN. School reopening and risks accelerating
437 the COVID-19 pandemic: A systematic review and meta-analysis protocol. *PLoS One*. 2021
438 Nov 17;16(11):e0260189. doi: 10.1371/journal.pone.0260189.
- 439 30. Gonçalves CA, Lopes-Júnior LC, Nampo FK, Zilly A, Mayer PCM, Pereira-da-Silva
440 G. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients
441 with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a
442 systematic review protocol. *BMJ Open*. 2019 Jul 17;9(7):e026975. doi: 10.1136/bmjopen-
443 2018-026975.
- 444 31. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile
445 app for systematic reviews. *Syst Rev*. 2016 Dec 5;5(1):210. doi: 10.1186/s13643-016-0384-
446 4.
- 447 32. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)*.
448 2012;22(3):276-82. PMID: 23092060; PMCID: PMC3900052.
- 449 33. Lopes-Júnior LC, Bomfim E, Olson K, Neves ET, Silveira DSC, Nunes MDR,
450 Nascimento LC, Pereira-da-Silva G, Lima RAG. Effectiveness of hospital clowns for
451 symptom management in paediatrics: systematic review of randomised and non-
452 randomised controlled trials. *BMJ*. 2020 Dec 16;371:m4290. doi: 10.1136/bmj.m4290.
- 453 34. Lopes-Júnior LC, Bomfim EO, Nascimento LC, Nunes MD, Pereira-da-Silva G, Lima RA.
454 Non-pharmacological interventions to manage fatigue and psychological stress in children
455 and adolescents with cancer: an integrative review. *Eur J Cancer Care (Engl)*. 2016
456 Nov;25(6):921-935. doi: 10.1111/ecc.12381.
- 457 35. Armstrong R, Hall BJ, Doyle J, Waters E. Cochrane Update. 'Scoping the scope' of a
458 cochrane review. *J Public Health (Oxf)*. 2011 Mar;33(1):147-50. doi:
459 10.1093/pubmed/fdr015. PMID: 21345890.
- 460 36. Valaitis R, Martin-Misener R, Wong ST, MacDonald M, Meagher-Stewart D, Austin P,
461 Kaczorowski J, O-Mara L, Savage R; Strengthening Primary Health Care through Public
462 Health and Primary Care Collaboration Team. Methods, strategies and technologies used
463 to conduct a scoping literature review of collaboration between primary care and public
464 health. *Prim Health Care Res Dev*. 2012 Jul;13(3):219-36. doi:
465 10.1017/S1463423611000594.
- 466 37. Fineout-Overholt E, Melnyk BM, Stillwell SB, Williamson KM. Evidence-based
467 practice step by step: Critical appraisal of the evidence: part I. *Am J Nurs*. 2010
468 Jul;110(7):47-52. doi: 10.1097/01.NAJ.0000383935.22721.9c.38.
- 469 38. Critical Appraisal Tools - JBI. 2017. Disponível em [http://joannabriggs.org/research/](http://joannabriggs.org/research/critical-appraisal-tools.html)
470 [critical-appraisal-tools.html](http://joannabriggs.org/research/critical-appraisal-tools.html)
- 471 39. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
472 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021
473 Mar 29;372:n71. doi: 10.1136/bmj.n71.
- 474